Illustrated treatment of refractory immune thrombotic thrombocytopenic purpura with caplacizumab

Brandon Tse,1 Megan Buchholz,2 Katerina Pavenski3,4

DESCRIPTION

A 58-year-old woman was hospitalised with a relapse of thrombotic thrombocytopenic purpura (TTP). She was diagnosed with immune TTP 10 years ago and has had two previous relapses. Her first episode was treated with therapeutic plasma exchange (TPE) and high-dose steroids; two relapses, which occurred 3 years apart, were also additionally treated with rituximab. Rituximab treatment during the second relapse was discontinued early due to anaphylactic reaction to the third infusion. Previous acute complications of TTP included non-ST-elevation myocardial infarction.

Following the last episode, the patient had persistent ADAMTS13 deficiency (activity less than 5%), but declined further immunosuppressive treatment. On admission, she had altered level of consciousness and required intubation. Admission bloodwork (day 1) revealed a platelet count of 7×10^9/L, haemoglobin 110 g/L, lactate dehydrogenase 2558 U/L (ULN 195 U/L), haptoglobin 0.03 g/L (normal 0.30–2.00 g/L) and indirect bilirubin 59 µmol/L (ULN 12 µmol/L). Blood film showed RBC fragmentation and ADAMTS13 activity was less than 1%. She had evidence of acute kidney injury (admission creatinine 192 µmol/L, baseline 51 µmol/L) and cardiac ischaemia (troponin 2.643 µg/L, ULN 0.4 µg/L). CT of the head did not reveal any acute pathology. TPE was initiated with solvent-detergent treated plasma and continued daily. The patient also received methylprednisolone 1 g daily for 3 days, followed by high-dose steroids. Rituximab treatment (4 weekly doses of 375 mg/m²) was delayed due to concerns about anaphylaxis, but eventually was administered on day 7, with desensitisation protocol. She tolerated rituximab but had no improvement clinically. There was also no improvement in her counts, haemolytic or organ damage markers (figure 1). Photographs of patient plasma on day 1 and 9 are shown in figure 2A, demonstrating significant haemoglobinaemia. Caplacizumab was requested through a compassionate access programme. The patient commenced caplacizumab 1 mg on day 10, using Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura (HERCULES) trial dosing protocol.1 Over the next few days, platelet count and lactate dehydrogenase improved dramatically (figures 1 and 2) and so did haemoglobinaemia (see figure 2B). The patient’s clinical condition also improved; she was extubated and discharged from...
intensive care unit on day 15 of admission (day 6 of caplacizumab). TPE was discontinued on day 15 (after 15 exchanges), and the patient was discharged home on day 17. Her renal function has normalised, and she did not have any permanent neurological deficits. There were no bleeding complications. The patient received her third and fourth doses of rituximab and completed a steroid taper as an outpatient. During steroid taper, she developed a local allergic reaction at the site of caplacizumab injections. As she was in clinical remission, doing well and eager to stop therapy, a decision was made to discontinue caplacizumab (after 65 days of therapy) and monitor her laboratory tests frequently. Her ADAMTS13 activity remained severely deficient, but she declined any further immunosuppression and to date has not relapsed.

This case report illustrates clinical and laboratory evolution of a patient with TTP refractory to standard of care therapies following addition of caplacizumab, adding to the few existing reports in the literature.2–4

Correction notice This article has been corrected since published online first. The Competing interest statement has been updated.

Twitter Brandon Tse @BrandonTse3

REFERENCES